ANI PHARMACEUTICALS INC - 8-K Filing
ANI Pharmaceuticals enters $676 million senior bridge facility to finance recommended cash offer for Egetis Therapeutics (Items: 1.01 Entry into a Material Definitive Agreement On November 4, 2026, ANI Pharmaceuticals, Inc, 8.01 The Credit Agreement will initially be unsecured and, upon funding thereunder (if any), will be guaranteed by certain subsidiaries of the Com, 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant The information required by, 9.01 Exhibits (d) Exhibits Exhibit No)
Tickers: $ANIP